Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 106, Issue 9, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/dju239
Keywords
-
Categories
Funding
- National Science and Technology Major Project [2012ZX10002-015, 2013ZX09301301]
- National Natural Science Foundation of China [81172144]
- Hi-tech Research and Development Program of China [2012AA020806]
Ask authors/readers for more resources
To assess the efficacy of combining radioimmunoconjugate [I-131] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. Patients received either RFA followed by [I-131] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one-and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[I-131] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)-positive subpopulation (P = .007). [I-131] metuximab may yield prevention of tumor recurrence after RFA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available